These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

103 related items for PubMed ID: 3120775

  • 21. Monoclonal antibody interferes with fibrin binding of t-PA.
    Matsuo O, Okada K, Fukao H, Tanaka N, Ueshima S.
    Thromb Res; 1988 Sep 01; 51(5):485-94. PubMed ID: 2459803
    [Abstract] [Full Text] [Related]

  • 22. Functional characterization of monoclonal antibodies directed against fibrin binding domains of tissue-type plasminogen activator.
    Wojta J, Beckmann R, Turcu L, Wagner OF, van Zonneveld AJ, Binder BR.
    J Biol Chem; 1989 May 15; 264(14):7957-61. PubMed ID: 2470738
    [Abstract] [Full Text] [Related]

  • 23. Study on the mechanism of action of heparin and related substances on the fibrinolytic system: relationship between plasminogen activators and heparin.
    Pâques EP, Stöhr HA, Heimburger N.
    Thromb Res; 1986 Jun 15; 42(6):797-807. PubMed ID: 3088755
    [Abstract] [Full Text] [Related]

  • 24. Purification and characterization of a novel, oligomeric, plasminogen kringle 4 binding protein from human plasma: tetranectin.
    Clemmensen I, Petersen LC, Kluft C.
    Eur J Biochem; 1986 Apr 15; 156(2):327-33. PubMed ID: 3009181
    [Abstract] [Full Text] [Related]

  • 25. The potential mechanism for the effect of heparin on tissue plasminogen activator-mediated plasminogen activation.
    Liang JF, Li Y, Yang VC.
    Thromb Res; 2000 Mar 01; 97(5):349-58. PubMed ID: 10709911
    [Abstract] [Full Text] [Related]

  • 26. Soluble fibrin degradation products potentiate tissue plasminogen activator-induced fibrinogen proteolysis.
    Weitz JI, Leslie B, Ginsberg J.
    J Clin Invest; 1991 Mar 01; 87(3):1082-90. PubMed ID: 1900308
    [Abstract] [Full Text] [Related]

  • 27. Characterization of functional domains in human tissue-type plasminogen activator with the use of monoclonal antibodies.
    Holvoet P, Lijnen HR, Collen D.
    Eur J Biochem; 1986 Jul 01; 158(1):173-7. PubMed ID: 3089776
    [Abstract] [Full Text] [Related]

  • 28. The fibrin-binding site of human plasminogen. Arginines 32 and 34 are essential for fibrin affinity of the kringle 1 domain.
    Váli Z, Patthy L.
    J Biol Chem; 1984 Nov 25; 259(22):13690-4. PubMed ID: 6094526
    [Abstract] [Full Text] [Related]

  • 29. Binding of fibrin fragments to one-chain and two-chain tissue-type plasminogen activator.
    Hasan AA, Chang WS, Budzynski AZ.
    Blood; 1992 May 01; 79(9):2313-21. PubMed ID: 1571544
    [Abstract] [Full Text] [Related]

  • 30. Fibrin and plasminogen structures essential to stimulation of plasmin formation by tissue-type plasminogen activator.
    Suenson E, Petersen LC.
    Biochim Biophys Acta; 1986 Apr 22; 870(3):510-9. PubMed ID: 2938632
    [Abstract] [Full Text] [Related]

  • 31. A steady-state template model that describes the kinetics of fibrin-stimulated [Glu1]- and [Lys78]plasminogen activation by native tissue-type plasminogen activator and variants that lack either the finger or kringle-2 domain.
    Horrevoets AJ, Pannekoek H, Nesheim ME.
    J Biol Chem; 1997 Jan 24; 272(4):2183-91. PubMed ID: 9036151
    [Abstract] [Full Text] [Related]

  • 32. Involvement of finger domain and kringle 2 domain of tissue-type plasminogen activator in fibrin binding and stimulation of activity by fibrin.
    Verheijen JH, Caspers MP, Chang GT, de Munk GA, Pouwels PH, Enger-Valk BE.
    EMBO J; 1986 Dec 20; 5(13):3525-30. PubMed ID: 3030730
    [Abstract] [Full Text] [Related]

  • 33. Interactions between the finger and kringle-2 domains of tissue-type plasminogen activator and plasminogen activator inhibitor-1.
    Kaneko M, Sakata Y, Matsuda M, Mimuro J.
    J Biochem; 1992 Feb 20; 111(2):244-8. PubMed ID: 1314812
    [Abstract] [Full Text] [Related]

  • 34. Structural domains of human tissue-type plasminogen activator that confer stimulation by heparin.
    Stein PL, van Zonneveld AJ, Pannekoek H, Strickland S.
    J Biol Chem; 1989 Sep 15; 264(26):15441-4. PubMed ID: 2504721
    [Abstract] [Full Text] [Related]

  • 35. Lipoprotein(a), fibrin binding, and plasminogen activation.
    Loscalzo J, Weinfeld M, Fless GM, Scanu AM.
    Arteriosclerosis; 1990 Sep 15; 10(2):240-5. PubMed ID: 2138452
    [Abstract] [Full Text] [Related]

  • 36. Plasmin-mediated fibrinolysis by variant recombinant tissue plasminogen activators.
    Urano S, Metzger AR, Castellino FJ.
    Proc Natl Acad Sci U S A; 1989 Apr 15; 86(8):2568-71. PubMed ID: 2523073
    [Abstract] [Full Text] [Related]

  • 37. Actin stimulates plasmin generation by tissue and urokinase-type plasminogen activators.
    Lind SE, Smith CJ.
    Arch Biochem Biophys; 1993 Nov 15; 307(1):138-45. PubMed ID: 8239651
    [Abstract] [Full Text] [Related]

  • 38. Effects of intact fibrin and partially plasmin-degraded fibrin on kinetic properties of one-chain tissue-type plasminogen activator.
    Fischer BE, Will H.
    Biochim Biophys Acta; 1990 Oct 18; 1041(1):48-54. PubMed ID: 2145980
    [Abstract] [Full Text] [Related]

  • 39. Autonomous functions of structural domains on human tissue-type plasminogen activator.
    van Zonneveld AJ, Veerman H, Pannekoek H.
    Proc Natl Acad Sci U S A; 1986 Jul 18; 83(13):4670-4. PubMed ID: 3088564
    [Abstract] [Full Text] [Related]

  • 40. Mechanism of the stimulatory effect of native fucoidan, highly sulfated fucoidan and heparin on plasminogen activation by tissue plasminogen activator: the role of chloride.
    Lang D, Williams T, Phillips A, Doctor VM.
    Eur J Drug Metab Pharmacokinet; 2004 Jul 18; 29(4):269-75. PubMed ID: 15726889
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.